Price data is not available

The average analyst price target for Xilio Therapeutics is $33.33, 304.0% above the current price. Of 2 analysts, 2 rate it Buy. Targets range from $16 to $56. The latest change came on Oct 21, 2026, when Raymond James initiated coverage of Xilio Therapeutics with an Outperform rating and a $16 price target.
Price Target Range — 3 Quarters
Analyst Consensus — 2 Analysts
Rating Trend — Last 9 Months